Skip to main content

Table 1 Clinical characteristics of the patients with endoscopically suspected Barrett’s esophagus ≥ 1 cm

From: Association between obesity and Barrett’s esophagus in a Japanese population: a hospital-based, cross-sectional study

 

PPI non-users

PPI users

 

Controls

ESBE ≥ 1 cm

P

Controls

ESBE ≥ 1 cm

P

Number

840 (69.2)

68 (5.6)

-

256 (69.8)

23 (6.3)

-

 

SIM

-

19/49 (38.8)

-

-

8/18 (44.4)

-

Patients profile

      
 

Age, y

56.2 ± 14.8

58.3 ± 13.6

0.31

63.5 ± 15.3

67.5 ± 12.4

0.26

 

Male sex

464 (55.2)

47 (69.1)

0.03

129 (50.4)

14 (60.9)

0.34

 

Alcohol drinking

244 (29.0)

20 (29.4)

0.95

54 (21.1)

8 (34.8)

0.13

 

Current smoking

173 (20.6)

14 (20.6)

0.99

34 (13.3)

3 (13.0)

> 0.99

 

GERD symptoms

126 (15.0)

12 (17.6)

0.56

74 (28.9)

9 (39.1)

0.30

Endoscopic findings

      
 

Reflux esophagitis

68 (8.1)

17 (25.0)

<0.0001

22 (8.6)

8 (34.8)

0.0001

 

Gastric atrophy (Open-type)

158 (18.8)

16 (23.5)

0.34

96 (37.5)

6 (26.1)

0.28

  1. PPI proton pump inhibitor, ESBE endoscopically suspected Barrett’s esophagus, SIM specialized intestinal metaplasia, GERD gastroesophageal reflux disease, NS not significant.